基于儿童药物利用指数的儿科支气管肺炎吸入用药合理性分析  

Rationality Analysis of Inhaled Medication for Pediatric Bronchopneumonia Based on Children DrugUtilization Index

作　　者：江军飞 高悦[1] 刘冲 Jiang Junfei;Gao Yue;Liu Chong(Shanghai Songjiang District Center Hospital,Shanghai 201600,China)

机构地区：[1]上海市松江区中心医院,上海201600

出　　处：《儿科药学杂志》2023年第4期11-13,共3页Journal of Pediatric Pharmacy

基　　金：上海市松江区科委课题,编号20sjkjgg130。

摘　　要：目的:采用儿童药物利用指数(cDUI)评价松江区中心医院儿科支气管肺炎吸入药物合理用药情况。方法:采用回顾性研究方法分析上海市松江区中心医院2018-2021年儿科诊断为支气管肺炎的1 493例住院患儿资料,提取其中使用吸入用布地奈德混悬液或硫酸特布他林雾化液的病例(共1 331例)并计算cDUI。结果:吸入用布地奈德混悬液的cDUI为2.79,硫酸特布他林雾化液的cDUI分别为>20 kg组0.25、≤20 kg组为0.50。结论:通过cDUI评价儿科支气管肺炎在应用吸入用布地奈德混悬液及硫酸特布他林雾化液方面存在不合理现象,问题主要集中在用药剂量、使用频次及适应证方面,临床需引起重视。Objective:To evaluate the rational application of inhalant drugs in the treatment of pediatric bronchopneumonia in Songjiang District Central Hospital by using children drug utilization index(cDUI).Methods:A retrospective study was utilized to analyze the data of 1,493 hospitalized children discharged from Pediatrics Department in Songjiang District Central Hospital from 2018 to 2021,and the cDUI values of inhaled budesonide suspension or terbutaline sulfate atomized solution were extracted and calculated.Results:The cDUI of budesonide suspension for inhalation was 2.79,and that of terbutaline sulfate atomized solution was 0.25 in>20 kg group,and 0.50 in⩽20 kg group respectively.Conclusion:There are a lot unreasonable phenomena in the application of inhaled budesonide suspension and terbutaline sulfate aerosol in the evaluation of bronchopneumonia by cDUI.The problems mainly concentrate on the dosage,frequency of use and indications,which needs attention in clinical application.

关 键 词：儿童药物利用指数 支气管肺炎 布地奈德混悬液 硫酸特布他林雾化液 

分 类 号：R969.3[医药卫生—药理学]